

In a promising boost for India’s healthcare innovation scene, Nivaan Care—a speciality chain tackling chronic pain—has raised $7 million in a Series A funding round. Led by Sorin Investments with participation from existing backers W Health Ventures, Endiya Partners, and Rebright Partners, this capital injection arrives at a critical time. The New Delhi-based startup, founded in 2023, plans to channel the funds into expanding its clinic network, beefing up clinical and operational infrastructure, and refining its patient-centric model. For millions grappling with persistent pain, this could mark a turning point in accessible, non-surgical care.
Nivaan Care‘s Series A builds on a strong foundation, following a $4.25 million seed round back in February 2025. This brings their total funding to over $11 million in under three years—a testament to investor faith in their vision. Sorin Investments took the lead, drawn by the startup’s full-stack approach and clinical edge. As Mandar Dandekar, Partner at Sorin, put it: “What stood out to us is Nivaan’s ability to create a full-stack solution backed by strong clinical acumen, thus giving it a clear first-mover advantage.“
The timing feels spot-on. Chronic pain affects nearly one in five Indian adults, yet options swing wildly from basic physiotherapy to drastic surgery. Nivaan Care slots into that gap with a multidisciplinary model blending pain physicians, physiotherapists, and care coordinators. They’ve already notched over 40,000 consultations and 5,000 minimally invasive procedures across clinics in Delhi-NCR, Mumbai, Jaipur, and Lucknow. Co-founder and CEO Nivesh Khandelwal captured the excitement: “This capital allows us to scale that model responsibly—by expanding our footprint, deepening clinical capabilities, and continuing to innovate on patient-first pain management solutions designed for India’s needs.“
Nivesh Khandelwal (CEO) and Vishwas Singh (COO) launched Nivaan Care in 2023, fueled by a shared frustration with fragmented pain care. Nivesh brings a blend of healthcare entrepreneurship and operational savvy, while Vishwas focuses on scaling systems efficiently. Their partnership mirrors the startup’s ethos: evidence-led interventions delivered through teamwork. Vishwas elaborated on expansion plans: “This round enables us to enter new markets such as Bengaluru while building the operational backbone required for expansion into select satellite cities.” It’s clear these two aren’t just building clinics—they’re crafting a network that prioritizes outcomes over volume.
From day one, they’ve zeroed in on common ailments like back, knee, and neck pain. No scalpels or long recoveries; instead, targeted, minimally invasive treatments that get patients moving faster. In a country where pain often goes unmanaged due to access barriers, their model feels like a breath of fresh air.
At its core, Nivaan Care operates single-speciality clinics that emphasize non-surgical relief. Imagine walking in with debilitating back pain and walking out with a personalized plan—no endless GP visits or risky ops. Their multidisciplinary teams deliver everything from advanced injections to physio regimens, all under one roof. This “middle layer” of care bridges primary treatments and extremes, using data-driven protocols tailored to Indian demographics.
The numbers speak volumes: Over 40,000 patients served in a short span shows real traction. Clinics in major hubs like Delhi-NCR and Mumbai handle high volumes, while Jaipur and Lucknow mark early forays into Tier-2 growth. Expansion to Bengaluru—a tech-health hotspot—promises to accelerate their reach, with satellite cities next on the horizon. Strengthening infrastructure means more specialized staff, cutting-edge equipment, and streamlined ops to handle surging demand.
Chronic pain isn’t just uncomfortable—it’s an economic drag, sidelining workers and straining families. In India, fragmented care leaves most sufferers in limbo. Nivaan Care flips the script by prioritizing minimally invasive options backed by evidence. They’re not alone in healthcare’s funding surge, but their niche focus gives them an edge. Sorin’s endorsement validates this, especially as investors hunt for scalable medtech plays amid rising wellness awareness.
Challenges loom, of course. Regulatory hurdles for new clinics, doctor shortages in emerging cities, and competition from general hospitals could test their mettle. Yet, with seed backers like Endiya and Rebright doubling down, Nivaan has the runway to iterate. Their patient-first mantra—rooted in local needs—could redefine pain management as empathetic and efficient.
The $7 million isn’t vaporware. Expect a flurry of new clinics, starting with Bengaluru’s bustling market. Clinical upgrades might include advanced imaging, robotic-assisted procedures, or AI-driven diagnostics down the line. Operations get a lift too: Better EMR systems, supply chain tweaks, and training programs to maintain quality at scale.
For patients, this means shorter wait times, wider access, and proven results. Nivesh’s words ring true—scaling responsibly ensures they don’t sacrifice care for speed. In satellite cities, where specialists are scarce, Nivaan could become the go-to for relief without travel.
Stakeholders are bullish. Nivesh envisions innovation tailored to India, from affordable protocols to tele-rehab hybrids. Vishwas eyes operational muscle for multi-city dominance. Mandar Dandekar’s nod highlights the first-mover moat: A full-stack setup that’s tough to replicate quickly.
Healthcare pros might appreciate the multidisciplinary angle—finally, pain care that coordinates like a well-oiled machine. For investors, it’s a bet on a $10B+ pain management market ripe for consolidation.
No startup sails smooth. Talent acquisition for pain specialists, insurance tie-ups for broader reach, and proving long-term efficacy through studies will be key. Economic pressures could slow elective spends, but rising middle-class health consciousness offsets that.
Opportunities abound: Partnerships with corporates for employee wellness, digital extensions like apps for home physio, and data insights to refine treatments. Nivaan Care’s early metrics position them to lead.
Nivaan Care’s $7 million Series A isn’t just funding—it’s fuel for a revolution in chronic pain care. From a 2023 startup to a multi-clinic chain with 40,000+ lives touched, Nivesh and Vishwas have built momentum that investors can’t ignore. As they fan out to Bengaluru and beyond, they’re poised to stitch a cohesive safety net for India’s overlooked pain sufferers.
In 2026, with healthcare digitizing fast, Nivaan Care exemplifies smart scaling: Clinical smarts meet operational grit. For patients weary of suffering in silence, brands eyeing wellness plays, and backers seeking impact, this is one to watch. Relief is expanding—one clinic, one intervention at a time.